8-K: CorMedix Reports Strong Q2 2026 Results, Raises EBITDA Guidance

CorMedix Therapeutics announced robust second quarter 2026 financial results, including $101.9 million in consolidated revenue and $26.0 million in net income, while raising its full-year adjusted EBITDA guidance.

Summary

• CorMedix Inc. reported strong financial results for the second quarter ended June 30, 2026.
• Consolidated revenue reached $101.9 million, a significant increase from $39.7 million in the same period of 2025.
• Net income for the quarter was $26.0 million, or $0.33 per basic share and $0.29 per diluted share.
• Adjusted EBITDA was $58.7 million for Q2 2026, up from $22.4 million in Q2 2025.
• DefenCath sales contributed $66.1 million, and the acquired Melinta portfolio added $35.8 million in revenue.
• The company maintains its full-year 2026 consolidated revenue guidance of $325 to $345 million.
• Full-year 2026 adjusted EBITDA guidance has been raised to a range of $125 to $140 million.
• Cash and short-term investments totaled $256.7 million as of June 30, 2026.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, with significant revenue growth, improved profitability, and raised guidance, indicating robust operational performance and positive future prospects.

Positives

• Significant year-over-year revenue growth, with consolidated revenue increasing to $101.9 million in Q2 2026 from $39.7 million in Q2 2025.
• Strong net income of $26.0 million and adjusted EBITDA of $58.7 million in Q2 2026.
• Raised full-year 2026 adjusted EBITDA guidance to $125-$140 million.
• Maintained full-year 2026 consolidated revenue guidance of $325-$345 million.
• DefenCath sales continue to perform well, contributing $66.1 million in Q2 2026.
• The acquired Melinta portfolio is contributing significantly, with $35.8 million in Q2 2026 revenue.
• A new multi-year commercial supply agreement for DefenCath was signed with a Large Dialysis Operator (LDO).
• The company has a strong cash position of $256.7 million, sufficient to fund operations for at least twelve months.

Negatives

• Total operating expenses increased significantly by approximately 87% to $34.2 million in Q2 2026 from $18.3 million in Q2 2025, largely due to the Melinta acquisition.
• Research and development expenses more than doubled to $6.7 million in Q2 2026 from $2.4 million in Q2 2025.
• Selling and marketing expenses increased by approximately 95% to $12.4 million in Q2 2026 from $6.4 million in Q2 2025.
• General and administrative expenses increased by approximately 59% to $15.1 million in Q2 2026 from $9.5 million in Q2 2025.

Risks

• The company faces risks related to the successful completion of future clinical trials, including patient enrollment and data generation for regulatory approval.
• There is a risk of unexpected safety or efficacy concerns related to product candidates.
• Continued pricing pressures and the impact of governmental and private payers on pricing, reimbursement, and patient access to pharmaceuticals are ongoing risks.
• Intellectual property protection for certain products may expire, leading to competition from generic and biosimilar products.
• The company is subject to risks associated with the integration and performance of acquired businesses, such as the Melinta portfolio.
• The company is involved in ongoing securities litigation, although insurance reimbursement for legal fees was recognized.

Future Outlook

CorMedix maintains its full-year 2026 consolidated revenue guidance of $325 to $345 million and has raised its full-year adjusted EBITDA guidance to a range of $125 to $140 million. Cash OpEx guidance is narrowed to $145 to $155 million. The company anticipates FDA submission of the sNDA for REZZAYO for an expanded indication in the third quarter of 2026, with potential agency action in H1 2027.

Management Comments

• "CorMedix delivered a strong second quarter, generating $101.9 million in consolidated revenue and $58.7 million of adjusted EBITDA, reflecting continued execution across our business."
• "We remain confident in our full-year 2026 outlook and our revenue and adjusted EBITDA guidance as we continue to navigate the post-TDAPA reimbursement environment for DefenCath with discipline and focus."
• "We also made meaningful progress across our pipeline and expect the near-term submission of the REZZAYO sNDA for prophylaxis."
• "With a strong balance sheet, meaningful cash position, and a disciplined capital allocation strategy, we believe CorMedix is well positioned to support our commercial priorities, advance high-value development programs, and create sustainable long-term value for shareholders."

Industry Context

StockSavvy.ai notes that CorMedix's strong Q2 performance, particularly the growth in DefenCath sales and the contribution from the Melinta acquisition, aligns with a trend of consolidation and portfolio expansion within the biopharmaceutical sector. The raised EBITDA guidance suggests effective cost management and operational leverage, which are critical in navigating the current reimbursement landscape for specialized therapeutics.

Legal Proceedings

• The company is involved in ongoing securities litigation.

Stakeholder Impact

• Shareholders: Potential for increased long-term value due to strong financial performance, raised guidance, and strategic pipeline development.
• Customers (Dialysis Centers): Continued access to DefenCath, with expanded commercial contracts and potential for new indications.
• Employees: Increased operational expenses suggest growth and potential for expanded roles, though also reflect costs of a larger combined company.
• Suppliers: Increased demand for products may lead to greater business opportunities.

Next Steps

• Anticipate FDA submission of the sNDA for REZZAYO for an expanded indication in the third quarter of 2026.
• Begin a pilot program with the new Large Dialysis Operator (LDO) in the third quarter of 2026.
• Await FDA agency action on the REZZAYO sNDA application in H1 2027, provided the application is accepted for review.

Key Dates

Recommendation

The filing demonstrates exceptionally strong financial performance with significant revenue growth, improved profitability, and raised future guidance. The company's robust cash position, strategic commercial agreements, and promising pipeline developments for REZZAYO indicate substantial upside potential, warranting a strong buy recommendation for seasoned investors and institutions.

Keywords

CorMedix Therapeutics, DefenCath, REZZAYO, Melinta portfolio, biopharmaceutical, financial results, EBITDA guidance, revenue